20xx年醫(yī)學(xué)專題—lecture8-白細(xì)胞分化抗原和黏附分子-資料下載頁(yè)
2024-10-31 18:33本頁(yè)面
【正文】 cyte emigration from the thymus. Eur J Immunol. (2000),TDL,thoracic duct lymph,第五十九頁(yè)，共六十七頁(yè)。,FTY720 engages S1P receptors,Lymph Node,Lymphatic vessel,T cell ~ 8 hr B cell ~16 hr,exit,第六十頁(yè)，共六十七頁(yè)。,Sphingosine 1phosphate (S1P),Abundant in plasma (~1uM) and lymph (~0.1uM) Made intracellulary by all cell types during sphingolipid degradation but only secreted by some cell types Ligand for a family of Gprotein coupled receptors (S1P15, formerly known as EDG receptors) S1P receptors have roles in blood vessel and heart development,Sphingosine,S1P,Ethanolamine + Hexadecanal,SphK,S1P phosphatase,S1P lyase,S1P1 (edg1),S1P2 (edg5),S1P4 (edg6),S1P5 (edg8),S1P3 (edg3),第六十一頁(yè)，共六十七頁(yè)。,Lymphoid Organ,,S1P1 wt,S1P1 is required intrinsically in lymphocytes for: T cell egress from the thymus T and B cell egress from peripheral lymphoid organs,,,,,,,,,,,,,,,,,,,,,,,20,60,100,140,180,Blood,Spleen,Peripheral LNs,Mesenteric LNs,Peyer’s Patches,Lymph,wt,ko,CD4 T,% of cotransferred wt control,Matloubian, Lo, Cinamon, Cyster Nature 2004,第六十二頁(yè)，共六十七頁(yè)。,,,blood,thymus, spleen,S1P1,S1P,,,,,,S1P lyase,radiation resistant cells,,,RBC,,,,,,,,,lymph,lymph node, Peyer’s patch,S1P1,,S1P,,,,,,S1P lyase,radiation resistant cells,,,Lymphocytes express S1P1 and exit lymphoid organs in response to S1P,S1P is abundant in blood and lymph RBC major source of blood S1P Lymphatic endothelial cells are source of lymph S1P Extracellular S1P is kept low inside lymphoid tissue S1P1 is a point of egress control,Lymphatic Endothelial cells,第六十三頁(yè)，共六十七頁(yè)。,Lymphoid Organ,,S1P1 wt,S1P1 is required for exit,But…,第六十四頁(yè)，共六十七頁(yè)。,FTY720indeuced inhibition of T cells egress from lymph node,第六十五頁(yè)，共六十七頁(yè)。,FTY720 (‘Gilenya’) approved for MS,East Hanover, NJ, September 22, 2010 Today Novartis announced that the FDA approved the oral multiple sclerosis (MS) treatment Gilenya(TM) (fingolimod/FTY720) 0.5 mg daily, a firstline treatment for relapsing forms of multiple sclerosis the most common forms of the disease. The FDA approval makes Gilenya the first oral treatment indicated for relapsing forms of MS available in the US. Gilenya (FTY720) is the first in a new class of drugs called S1PR modulators. In MS, the immune system damages the covering that protects nerve fibers in the CNS. Gilenya39。s novel mechanism is unknown, but it is thought to work by reducing the immune system39。s attack on the CNS by retaining certain lymphocytes in the lymph nodes. This prevents them from reaching the CNS, where they could potentially attack the protective covering around the nerve fibers, resulting in less inflammatory damage to the nerve cells.,第六十六頁(yè)，共六十七頁(yè)。,內(nèi)容(n232。ir243。ng)總結(jié),白細(xì)胞分化抗原和黏附分子。主要結(jié)合粒細(xì)胞譜系,此外還結(jié)合NK、B和CD8+T細(xì)胞。以CD命名(m236。ng m237。ng)：統(tǒng)稱為CD抗原/分子。淋巴細(xì)胞歸巢(lymphocyte homing)是淋巴細(xì)胞遷移的一種特殊形式，包括：。（1）淋巴干細(xì)胞向中樞淋巴器官的歸巢。（4）淋巴細(xì)胞向炎癥部位(如皮膚,腸道粘膜和關(guān)節(jié)滑膜等炎癥部位)的滲 出。But,第六十七頁(yè)，共六十七頁(yè)
數(shù)學(xué)相關(guān)推薦
鄂ICP備17016276號(hào)-1